Spain Antifungal Drugs Market Size & Outlook, 2023-2030
Spain antifungal drugs market, 2018-2030 (US$M)
Related Markets
Spain antifungal drugs market highlights
- The Spain antifungal drugs market generated a revenue of USD 251.5 million in 2023 and is expected to reach USD 300.0 million by 2030.
- The Spain market is expected to grow at a CAGR of 2.5% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 251.5 million |
| Market revenue in 2030 | USD 300.0 million |
| Growth rate | 2.5% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Spain accounted for 1.6% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.91% in 2023. Horizon Databook has segmented the Spain antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
The Spanish Agency for Medicines and Health Products (AEMPS) is the national healthcare authority responsible for the regulation of medicines in Spain. It was established in 1999 as the health authority of reference for healthcare professionals and citizens in the field of quality assurance, efficiency, safety, and information & accessibility to drugs.
The generic drugs are regulated as per the law 29/2006 passed on July 2006, which protects the coherent use of medical devices and medicines, and Royal Decree 1345/2007 of October 2007, which regulates the authorization, registration, and supply of medicinal products for treating patients.
The average time for generic drug approval is more than 14 months, which is second to Greece in the EU. Thus, delays in the approval of new medicine are anticipated to restrain the market. The marketing authorization is granted based on scientific criteria of quality, safety, and efficacy of the medicinal product.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain antifungal drugs market size, by drug class, 2018-2030 (US$M)
Spain Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
